These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9191245)

  • 1. Is the success of BCG tumour immunotherapy due to the induction of co-stimulatory molecules?
    Alexandroff AB; Mitchell I; Black J; James K
    Biochem Soc Trans; 1997 May; 25(2):201S. PubMed ID: 9191245
    [No Abstract]   [Full Text] [Related]  

  • 2. [BCG-instillation therapy in superficial bladder tumor--host immune response elicited by local application of BCG].
    Hayakawa M; Hatano T; Saito S; Miyazato T; Nakayama M; Igarashi M; Saita H
    Nihon Hinyokika Gakkai Zasshi; 1987 Nov; 78(11):1972-81. PubMed ID: 3502480
    [No Abstract]   [Full Text] [Related]  

  • 3. [Studies on stimulation of immunological responses resulting from intravesical BCG instillation in patients with bladder carcinomas].
    Tachibana M; Jitsukawa S; Deguchi N; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1680-5. PubMed ID: 3251104
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
    Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
    Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy of superficial bladder cancer].
    Schmitz-Dräger BJ; Schattka SO; Ebert T
    Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.
    Jackson AM; Alexandroff AB; McIntyre M; Esuvaranathan K; James K; Chisholm GD
    J Clin Pathol; 1994 Apr; 47(4):309-12. PubMed ID: 7913098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
    Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
    An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Focus on tumor immunology of transitional cell carcinoma].
    Olbert PJ; Schrader AJ; Hegele A; Hofmann R
    Urologe A; 2007 Sep; 46(9):1135-7. PubMed ID: 17605116
    [No Abstract]   [Full Text] [Related]  

  • 12. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
    Zlotta AR; van Vooren JP; Huygen K; Drowart A; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Simon J; Schulman CC
    Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Salvatore Siracusano, Francesca Vita, Rita Abbate, Stefano Ciciliato, Violetta Borelli, Massimiliano Bernabei and Giuliano Zabucchi. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 2007;51:1589-99.
    Brandau S; Suttmann H
    Eur Urol; 2007 Oct; 52(4):1266-7; author reply 1268-9. PubMed ID: 17560711
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapeutic strategies for high-risk bladder cancer.
    Sharma P; Old LJ; Allison JP
    Semin Oncol; 2007 Apr; 34(2):165-72. PubMed ID: 17382800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of surface CD40 and immunocytochemical actin-bundling protein fascin in dendritic cells from multiple myeloma treated with retinoids during their differentiation in vitro.
    Chiriva-Internati M; Grizzi F; Franceschini B; Hermonat PL; Lim S; Dioguardi N; Rodriguez FM
    In Vitro Cell Dev Biol Anim; 2001; 37(10):641-3. PubMed ID: 11776968
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
    D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
    J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of intravesical chemotherapy and immunotherapy.
    Sarosdy MF
    Urol Clin North Am; 1992 Aug; 19(3):509-19. PubMed ID: 1636235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
    Witjes JA; vd Meijden AP; Debruyne FM
    Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Herr HW
    J Urol; 1987 Aug; 138(2):409-10. PubMed ID: 3599266
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.